Reading the tape
NASDAQ: CGEM
Cullinan Therapeutics, Inc.
Healthcare · Medical - Pharmaceuticals
Market Cap
$942.66M
52w High
$16.74
52w Low
$5.68
P/E
-4.13
Volume
2.29M
Outstanding Shares
61.45M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 85.49%FCF (TTM): 4.42%
What changed
The stock rose 85.49% over the last year. Free cash flow grew 4.42% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies.
CEONadim Ahmed
SectorHealthcare
IndustryMedical - Pharmaceuticals
Employees111
IPO dateJan 8, 2021
Valuation
Forward P/E—
EV/EBITDA-2.17
Enterprise value$525.52M
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-53.8%▼89.73%vs FY2024
Analyst consensus
RatingBuy
Target price$31.14▲103.00%
8
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.80 · Revenue est $3.67M
View